Article Text

PDF

The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care
  1. Jane Rebecca Smith1,
  2. Michael J Noble2,
  3. Stanley Musgrave1,
  4. Jamie Murdoch3,
  5. Gill M Price1,
  6. Garry R Barton1,
  7. Jennifer Windley2,
  8. Richard Holland1,
  9. Brian DW Harrison1,
  10. Amanda Howe1,
  11. David B Price4,
  12. Ian Harvey1,
  13. Andrew M Wilson1
  1. 1Norwich Medical School, University of East Anglia, Norwich, UK
  2. 2Acle Medical Centre, Acle, Norfolk, UK
  3. 3School of Nursing Sciences, University of East Anglia, Norwich, UK
  4. 4Research in Real Life Ltd, Cawston, Norfolk, UK
  1. Correspondence to Dr Jane Rebecca Smith, Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK; j.r.smith{at}uea.ac.uk

Abstract

Background Patients at risk of severe exacerbations contribute disproportionally to asthma mortality, morbidity and costs. We evaluated the effectiveness and costs of using ‘asthma risk registers’ for these patients in primary care.

Methods In a cluster-randomised trial, 29 primary care practices identified 911 at-risk asthma patients using British asthma guideline criteria (severe asthma plus adverse psychosocial characteristics). Intervention practices added electronic alerts to identified patients' records to flag their at-risk status and received practice-based training about using the alerts to improve patient access and opportunistic management. Control practices continued routine care. Numbers of patients experiencing the primary outcome of a moderate-severe exacerbation (resulting in death, hospitalisation, accident and emergency attendance, out-of-hours contact, or a course/boost in oral prednisolone for asthma), other healthcare and medication usage, and costs over 1 year were derived from practice-based records.

Results There was no significant effect on exacerbations (control: 46.5%; intervention: 53.6%, OR, 95% CI 1.30, 0.93 to 1.80). However, this composite outcome masked relative reductions in intervention patients experiencing hospitalisations (OR 0.50, 95% CI 0.26 to 0.94), accident and emergency (OR 0.74, 95% CI 0.42 to 1.31) and out-of-hours contacts (OR 0.79, 95% CI 0.45 to 1.37); and a relative increase in prednisolone prescription for exacerbations (OR 1.31, 95% CI 0.92 to 1.85). Furthermore, prescription of nebulised short-acting β-agonists reduced and long-acting β-agonists increased for intervention relative to control patients. The adjusted mean per patient healthcare cost was £138.21 lower (p=0.837) among intervention practices.

Conclusion Using asthma risk registers in primary care did not reduce treated exacerbations, but reduced hospitalisations and increased prescriptions of recommended preventative therapies without increasing costs.

  • Asthma
  • severe asthma
  • primary care
  • risk registers
  • cluster-randomised controlled trial
  • asthma in primary care
  • psychology
  • asthma guidelines
  • health economist
  • asthma epidemiology
  • asthma pharmacology
  • COPD epidemiology
  • COPD exacerbations
  • COPD pharmacology
  • interstitial fibrosis
  • pulmonary rehabilitation
View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This study was funded by Asthma UK (Project no. 06/047). Neither the funder nor sponsor had a role in the design, data collection, analysis, interpretation, writing up, or decision to submit for publication, responsibility for which rested solely with the authors.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by Norfolk Research Ethics Committee (reference number 06/Q0101/200).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.